Q2 2026 confirmed a decisive shift in biopharma partnering, from broad-based dealmaking toward selective, high-value collaborations. Deal volume fell 18% to 94 transactions and upfront commitments weakened, yet total deal value rose to $82.9B as a handful of large strategic partnerships lifted average deal size to about $882M from $691M. Therapeutic Platforms and Biopharma extended their lead as the sector’s primary growth engine, capturing the largest share of both activity and value, while Diagnostics, Sequencing, Omics, and Tools normalized after an exceptionally strong Q1. A thinner $100M+ Club and lower average and median upfronts point to sharper capital discipline, with buyers reserving large upfront outlays for only the most differentiated assets and platforms. H1 2026 closed with 209 partnerships worth $162.4B and $8.9B in upfront cash and equity, evidence that partnering demand remains strong but is now driven by strategic fit and asset quality rather than volume.
The quarter’s largest deals clustered around differentiated platforms, late-stage clinical assets, and global licensing structures. Pfizer and Innovent Biologics led at up to $10.5B across 12 oncology programs in ADCs and multispecific antibodies. Fosun Pharma and AriBio signed the quarter’s biggest neuroscience deal, a Phase III Alzheimer’s option worth up to $4.7B. Eli Lilly and Haisco Pharmaceutical formed a five-candidate small-molecule discovery alliance worth up to $3.0B, and Jazz Pharmaceuticals and AbCellera backed T-cell engagers for gastrointestinal and other solid tumors at up to $4.1B. Regeneron and Parabilis Medicines added a $2.2B antibody-helicon conjugate alliance. Across the five, the pattern held: scalable discovery platforms, oncology and neuroscience assets, and flexible global licensing that yields multiple candidates while pushing risk onto milestones.
In Q2 2026, Biopharma Therapeutics and Platforms R&D partnerships reflected a selective but higher-value environment. Deal volume declined 18% to 94 transactions from 115 in Q1 2026, while total deal value increased 4% to $82.9B from $79.5B. Consistent with this trend, average deal value per transaction rose from approximately $691M in Q1 to about $882M in Q2. Upfront investment, however, softened, with upfront cash and equity declining 18% to $4.0B, average upfront payments falling 29% to $93M, and median upfront payments dropping 50% to $30M. Overall, H1 2026 recorded 209 partnerships worth $162.4B, supported by $8.9B in upfront cash and equity.
Biopharma Therapeutics and Platforms vs Other Life Sciences
In Q2 2026, Biopharma Therapeutics and Platforms R&D partnerships by subsector declined 17% quarter over quarter to 114 deals from 138 in Q1. Therapeutic Platforms and Biopharma remained the dominant subsector, recording 72 deals in Q2 versus 75 in Q1, a modest 4% decline that underlines continued strength in core biopharma partnering. Diagnostics, Sequencing, Omics, and Tools experienced a steeper slowdown, with deal volume falling 30% to 32 from 46, while Manufacturing Tech and Others declined 53% to 8 deals from 17, reflecting weaker activity outside the core therapeutic platform segment. Medtech, Device, Digital Therapeutics, and Wearables recorded limited activity, with 2 deals in Q2 following no transactions in Q1. Overall, H1 2026 totaled 252 partnerships, led by Therapeutic Platforms and Biopharma with 147 deals, followed by Diagnostics, Sequencing, Omics, and Tools with 78 deals.
In Q2 2026, total deal value for Biopharma Therapeutics and Platforms R&D partnerships remained broadly stable at $83.2B, compared with $84.6B in Q1, a modest 2% quarter-over-quarter decline. However, the distribution of value shifted significantly across subsectors. Therapeutic Platforms and Biopharma reinforced their position as the primary value driver, with total deal value increasing 27% to $51.8B from $40.7B, reflecting stronger investment in core biopharma collaborations. Manufacturing Tech and Others also recorded a sharp increase, rising to $18.6B from $4.0B, indicating that a small number of large transactions significantly boosted the subsector’s value. In contrast, Diagnostics, Sequencing, Omics, and Tools declined 69% to $12.5B from $39.8B, reflecting a slowdown in high-value transactions relative to Q1. Medtech, Device, Digital Therapeutics, and Wearables remained a small contributor, generating $300M in Q2. Overall, H1 2026 total deal value reached $167.8B, led by Therapeutic Platforms and Biopharma at $92.5B, followed by Diagnostics, Sequencing, Omics, and Tools at $52.3B.
Biopharma Therapeutics and Platform R&D Partnership – R&D Partnerships $100M + Club
In Q2 2026, the $100 Million Plus Club for Biopharma Therapeutics and Platforms R&D partnerships slowed compared with Q1, reflecting a moderation in large upfront dealmaking. The number of deals declined 29% to 10 from 14, while total deal value fell 28% to $35.8B from $49.4B, indicating fewer high-value partnerships and lower overall transaction value. Total upfront cash and equity also decreased 23% to $3.1B from $4.0B. Overall, H1 2026 recorded 24 high-upfront R&D partnerships with a combined deal value of $85.2B and $7.2B in upfront cash and equity, highlighting that large-scale partnering remained robust despite weaker momentum in Q2.
Prominent R&D Partnerships Biopharma Therapeutics and Platforms in Q2 2026
Innovent Biologics development and commercialization deal with Pfizer – May 2026
Innovent Biologics granted Pfizer exclusive rights to develop and commercialize 12 cancer programs, including eight Innovent assets and four Pfizer discovery-stage candidates, focused on antibody-drug conjugates (ADCs) and multispecific antibodies. Innovent will lead discovery through Phase I, after which Pfizer will assume global late-stage development and commercialization. The collaboration includes four globally licensed programs, four licensed outside Greater China, and four co-developed programs with shared costs, US and Europe profit sharing, and Innovent retaining Greater China rights. Innovent will receive $650M upfront and is eligible for up to $9.9B in development, regulatory, and commercial milestones (breakout not disclosed), plus up to double-digit royalties.
AriBio license option deal with Fosun Pharma – May 2026
AriBio granted Fosun Pharma an exclusive worldwide option (excluding Korea, the Middle East, and Latin America) to develop, manufacture, and commercialize AR1001, a Phase III once-daily oral PDE-5 inhibitor for Alzheimer’s disease (AD) being evaluated in the global POLARIS-AD trial. AriBio is eligible for up to $4.7B, including a $60M option fee and an additional $80M upon topline Phase III results, bringing staged upfront payments to $140M. The deal also includes undisclosed sales milestones triggered at annual net sales of at least $2.5B and tiered double-digit royalties of up to approximately 20%. AriBio received the first $10M payment on May 26, 2026.
Haisco Pharmaceutical development and commercialization deal with Eli Lilly – May 2026
Haisco Pharmaceutical granted Eli Lilly exclusive rights to discover, develop, and commercialize 5 novel small-molecule candidates across multiple therapeutic areas. Haisco will conduct discovery, while Lilly will lead IND-enabling studies, clinical development, and commercialization, with exclusive global rights or rights outside China, Hong Kong, Macau, and Taiwan for selected programs. Haisco will receive $87M upfront and near-term payments and is eligible for up to $3.0B in development, regulatory, and commercial milestones (breakout not disclosed), plus single-digit tiered royalties.
Jazz Pharmaceuticals research partnership with AbCellera – June 2026
AbCellera partnered with Jazz Pharmaceuticals to discover T-cell engager (TCE) multispecific antibodies for gastrointestinal cancers and other solid tumors using its antibody discovery platform. AbCellera will lead discovery for the first 2 programs and a third within 12 months, with the collaboration expandable to 5 programs. Jazz holds exclusive worldwide commercialization options. AbCellera will receive $56M upfront for the first 2 programs and $28M upon initiation of the third and is eligible for up to $792M per program in option fees and development, regulatory, and commercial milestones (breakout not disclosed), plus mid-single- to low-double-digit royalties. If all 5 programs are exercised, the collaboration could be worth approximately $4.1B.
Parabilis development and commercialization deal with Regeneron – May 2026
Parabilis Medicines granted Regeneron worldwide rights to discover, develop, and commercialize antibody-helicon conjugates (AHCs) using its Helicon peptide platform across multiple undisclosed therapeutic areas. Regeneron will initially pursue 5 targets, with the option to expand the collaboration. Parabilis will receive $125M, including $50M upfront in cash and a $75M equity investment, and is eligible for up to approximately $2.2B in development, regulatory, and commercial milestones (breakouts not disclosed) across the initial five targets, plus undisclosed option payments for additional targets and low double-digit tiered royalties.
Also check out Global Healthcare and Life Sciences – Q2 2026 Review
